Interações de Deutetrabenazina

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (bula de Amiodarona, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (bula de Azitromicina, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Ciprofloxacino, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (bula de Dofetilida, Advertências)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (bula de Entricitabina + rilpivirina + tenofovir, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Drugs that Prolong the QT Interval : Avoid concomitant use. (bula de Fenobarbital, Interações medicamentosas)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (bula de Fluconazol, Contraindicações)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (bula de Foscarnete, Interações medicamentosas)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (bula de Fosfomicina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (bula de Hidroxicloroquina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (bula de Ivabradina, Advertências e precauções)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (bula de Levofloxacino, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (bula de Lopinavir + ritonavir, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (bula de Mirtazapina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (bula de Oxaliplatina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (bula de Pazopanibe, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (bula de Pitolisanto, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (bula de Propafenona, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (bula de Repaglinida, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Avoid the concomitant use of drugs known to prolong the QTc interval. (bula de Sertralina, Interações medicamentosas)

Taking tetrabenazine or valbenazine [see Drug Interactions ( 7.6 )] . (bula de Deutetrabenazina, Contraindicações)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Taking monoamine oxidase inhibitors (MAOIs). (bula de Deutetrabenazina, Contraindicações)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Taking tetrabenazine or valbenazine [see Drug Interactions ( 7.6 )] . (bula de Deutetrabenazina, Contraindicações)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (bula de Vepdegestranto, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Drug Interactions Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with β-blocking agents. (bula de Acebutolol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (bula de Arformoterol, Interações medicamentosas)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (bula de Atenolol, Interações medicamentosas)

Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (bula de Atenolol + clortalidona, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents. (bula de Betaxolol, Interações medicamentosas)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (bula de Bisoprolol, Interações medicamentosas)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (bula de Bisoprolol + hidroclorotiazida, Interações medicamentosas)

Catecholamine-depleting Drugs Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (bula de Brimonidina + timolol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (bula de Carvedilol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (bula de Citalopram, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Postganglionic Blocking Agents Agents such as reserpine potentiate cocaine-induced sympathetic stimulation; concurrent use may increase the risk of hypertension and cardiac arrhythmias that may be life-threatening. (bula de Cocaína, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (bula de Dorzolamida + timolol, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (bula de Efavirenz, Interações medicamentosas)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (bula de Efavirenz + lamivudina + tenofovir, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (bula de Eribulina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

…that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists Phosphodiesterase Type 5 inhibitors Mixed α- and β-receptor antagonists Calcium channel blockers, such as nifedipine Benzodiazepines ACE inhibitors Centrally acting sympatholytic agents, such as reserpine, guanfacine (bula de Fenilefrina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (bula de Formoterol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (bula de Glimepirida, Interações medicamentosas)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (bula de Glipizida, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Gosserrelina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Aspart is concomitantly administered with these drugs. (bula de Insulina asparte, Interações medicamentosas)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs. (bula de Insulina degludeca, Interações medicamentosas)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. (bula de Insulina detemir, Interações medicamentosas)

Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (bula de Insulina glargina, Interações medicamentosas)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (bula de Insulina lispro, Interações medicamentosas)

Mechanism and Clinical Effect(s) Concomitant use of pentamidine with AFREZZA may cause hypoglycemia, which may sometimes be followed by hyperglycemia Beta-blockers, Clonidine, Guanethidine, and Reserpine Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (bula de Insulina regular (humana), Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

TYKERB may prolong the QT interval in some patients. (bula de Lapatinibe, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Leuprorrelina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (bula de Mefloquina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (bula de Metoprolol, Interações medicamentosas)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (bula de Metoprolol + hidroclorotiazida, Interações medicamentosas)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (bula de Metronidazol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (bula de Mifepristona, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (bula de Moxifloxacino, Advertências e precauções)

Catecholamine-depleting drugs (e.g., reserpine) - additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension). (bula de Nadolol, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs. (bula de Nateglinida, Interações medicamentosas)

Reserpine or clonidine may produce excessive reduction of sympathetic activity. (bula de Nebivolol, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (bula de Pindolol, Interações medicamentosas)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (bula de Pioglitazona + glimepirida, Interações medicamentosas)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (bula de Ponesimode, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (bula de Primaquina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (bula de Rilpivirina, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (bula de Rocurônio, Advertências e precauções)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (bula de Sotalol, Interações medicamentosas)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (bula de Subcitrato de bismuto + metronidazol + tetraciclina, Advertências e precauções)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (bula de Sunitinibe, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (bula de Timolol, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (bula de Triptorrelina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (bula de Deutetrabenazina, Advertências e precauções)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Examples of acidifying agents include gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride, ascorbic acid) and urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts). (bula de Dextroanfetamina, Interações medicamentosas)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (bula de Efedrina, Interações medicamentosas)

Phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine. (bula de Fenoxibenzamina, Interações medicamentosas)